CHCs Help Low Income Patients with Rising Insulin Prices

Following Wednesday’s article about Apexus (the 340B Prime Vendor), The New York Times published a second article about 340B this week, focusing on how drops in the sticker price for insulin have impacted CHCs and their low-income patients. The article explains how lower “sticker prices” caused 340B prices for insulin to skyrocket last year, and how this has affected CHCs patients and operations. While the human impacts of these changes can be devastating, the article clearly shows how CHCs are good stewards of the 340B program, using it to expand access to affordable medications and other important services to low-income patients. For this reason, we advise CHCs to keep this article handy to share with policymakers.

The post CHCs Help Low Income Patients with Rising Insulin Prices appeared first on Pennsylvania Office of Rural Health.